Showing results (51-60 of 130) with videos related to

Sort By:
Pageof 13
JAMA Cardiology|November 14, 2019
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical TrialSubodh Verma, Stephen C Bain, John B Buse, et al.
Medicine and Science in Sports and Exercise|November 5, 2011
Isomaltulose improves glycemia and maintains run performance in type 1 diabetesRichard Michael Bracken, Rhydian Page, Benjamin Gray, et al.
Kidney International Reports|December 19, 2022
Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER ProgramsDavid Z I Cherney, Samy Hadjadj, Jack Lawson, et al.
Cardiovascular Diabetology|August 24, 2023
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysisPeter Rossing, Stephen C Bain, Heidrun Bosch-Traberg, et al.
Journal of Sports Sciences|December 15, 2010
A combined insulin reduction and carbohydrate feeding strategy 30 min before running best preserves blood glucose concentration after exercise through improved fuel oxidation in type 1 diabetes mellitusDaniel J West, Jeffrey W Stephens, Stephen C Bain, et al.
Diabetes, Obesity & Metabolism|May 4, 2023
Impact of severe hypoglycaemia requiring hospitalization on mortality in people with type 1 diabetes: A national retrospective observational cohort studyOthmar Moser, James Rafferty, Max L Eckstein, et al.
The New England Journal of Medicine|June 25, 2023
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous InsulinJulio Rosenstock, Stephen C Bain, Amoolya Gowda, et al.
The Lancet. Diabetes & Endocrinology|March 28, 2017
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trialVanita R Aroda, Stephen C Bain, Bertrand Cariou, et al.
Frontiers in Public Health|January 26, 2021
Improved Nocturnal Glycaemia and Reduced Insulin Use Following Clinical Exercise Trial Participation in Individuals With Type 1 DiabetesOlivia McCarthy, Rachel Deere, Max L Eckstein, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 24, 2021
Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population-based observational retrospective cohort studyKamlesh Khunti, Christin L Hertz, Lise Lotte N Husemoen, et al.
Pageof 13